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Abstract
Objective To investigate whether white matter microstructural changes can be used as a predictor of worsening of motor
features or cognitive decline in patients with Parkinson’s disease and verify whether white matter microstructural longitudinal
changes differ between patients with Parkinson’s disease with normal cognition and those with mild cognitive impairment.
Methods We enrolled 120 newly diagnosed patients with early stage Parkinson’s disease (27 with mild cognitive impairment and 93 with normal cognition) along with 48 controls. Participants were part of the incidence of cognitive impairment
in cohorts with longitudinal evaluation in Parkinson’s disease study and were assessed at baseline and 18 months later with
cognitive, motor tests and diffusion tensor imaging. The relationships between fractional anisotropy and mean diffusivity
with disease status, cognitive and motor function were investigated.
Results At baseline, patients with early stage Parkinson’s disease had significantly higher widespread mean diffusivity relative to controls, regardless of cognitive status. In patients with Parkinson’s disease/mild cognitive impairment, higher mean
diffusivity was significantly correlated with lower attention and executive function scores. At follow-up frontal mean diffusivity increased significantly when comparing patients with Parkinson’s disease/mild cognitive impairment with those with
normal cognition. Baseline mean diffusivity was a significant predictor of worsening of motor features in Parkinson’s disease.
Conclusions Mean diffusivity represents an important correlate of cognitive function and predictor of motor impairment in
Parkinson’s disease: DTI is potentially a useful tool in stratification of patients into clinical trials and to monitor the impact
of treatment on motor function.
Keywords Parkinson’s disease · Mild cognitive impairment · Assessment of cognitive disorders · Longitudinal study · DTI

Introduction
The incidence of dementia is five times greater in patients
with Parkinson’s disease (PD) than in the general population
[1]. Whether dementia is an inevitable event in PD is yet to
be established, but 83% of patients have dementia if alive at
20 years from onset [2]. Cognitive changes start early in PD
with 36% of newly diagnosed patients having mild cognitive impairment (PD-MCI) [3], of whom two-third develop
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article (https://doi.org/10.1007/s00415-018-8873-0) contains
supplementary material, which is available to authorized users.
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dementia within 4 years [4]. Elucidating the pathophysiological mechanisms underlying cognitive impairment in
PD may, therefore, influence patients’ treatment selection
and response monitoring early in their illness.
White matter lesions correlate with motor and cognitive
abnormalities in otherwise healthy elderly individuals, and
are predicted to contribute to clinical symptoms in PD [5].
Increased volume of white matter lesions has been described
in PD, especially in those with dementia [6]. Even slight
changes in the WM, as identified by diffusion tensor imaging (DTI), might contribute to the cognitive decline in PD
[7, 8]. Diffusion tensor parameters such as mean diffusivity
(MD) and fractional anisotropy (FA) are established markers
of white matter microstructure and can demonstrate subtle
damage even when clinical structural imaging shows normal
appearing white matter [7].
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We therefore, proposed that white matter change is a
major contributor to cognitive decline in PD. Although the
underlying pathophysiological process of PD dementia is
likely to be heterogeneous [9] we have previously shown
that in the early stages of PD, there are increases in MD
even when there is no significant grey matter volume loss
[10], suggesting that MD may be an early biomarker of this
state. Monitoring white matter changes with DTI offers a
non-invasive biomarker which could reflect a mechanism
underlying cognitive impairment in PD. We tested the specific hypothesis that longitudinal white matter microstructural changes, characterised by decrease in FA and increase
in MD, are more pronounced among patients with PD-MCI
than those with PD who are cognitively normal at baseline.
Further, we tested whether baseline white matter abnormalities can be used as a predictor of cognitive decline or worsening of motor impairment.

Methods
The study was approved by the Newcastle and North
Tyneside Research Ethics Committee and has, therefore,
been performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its later
amendments. All participants provided informed consent prior to their inclusion in the study. Participants were
selected from the Incidence of Cognitive Impairment in
Cohorts with Longitudinal Evaluation in Parkinson’s Disease (ICICLE-PD) study. The protocol has been described
elsewhere [11], but in summary, we recruited 157 newly
diagnosed patients with idiopathic PD, by United Kingdom
PD Brain bank criteria [12], from community and outpatient
clinics in Newcastle upon Tyne/Gateshead. Unrelated controls (n = 99), aged 45 years and over were recruited from
the local community.
Exclusion criteria were: insufficient knowledge of English; dementia according to Movement Disorder Society
(MDS) criteria [13] or significant memory impairment as
evidenced by a Mini-Mental State Examination (MMSE)
[14] score of < 24 at presentation, drug-induced parkinsonism, progressive supranuclear palsy, multiple system atrophy
or corticobasal degeneration.
Structured interviews included demographic data, neurologic examination, the Movement Disorders Society Unified PD Rating Scale part III (UPDRS-III) [15], Hoehn and
Yahr stage [16] and neuropsychological tests covering all
cognitive domains [17]. Performances on the individual
tasks were transformed into z-scores and the average in
each cognitive domain was calculated [18]. For data that
were not normally distributed and could not be transformed
appropriately, percentiles derived from a normal distribution
were used to estimate cut-offs 1 SD (16th percentile), 1.5
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SD (7th percentile) and 2 SD (2nd percentile), therefore, the
cut-offs give approximately the correct percentage of people
impaired. For example, the pentagon score was assessed as
2 (shape includes 10 angles and clear intersection), 1 (two
intersecting figures, one with five angles) or 0 (less acceptable copy); using corresponding percentiles from the control group, participants scoring 1 were classified as having
impairment at the 1 SD and 1.5 SD level, and participants
scoring 0 were classified as having impairment at the 2 SD
level [17]. Assessments were completed in an ‘on’ motor
state. Clinical phenotypes of tremor dominant (TD) and
postural instability/gait disorder (PIGD) were derived from
the UPDRS scores [19]. PD medications were recorded and
levodopa equivalent daily dose was calculated [20].
Using the MDS Task Force criteria [21], PD-MCI was
diagnosed when patients scored 2 SD below normative
means on at least two cognitive tests either in two different
cognitive domains (attention, memory, language, executive
and visuospatial functions) or two tests in the same domain.
The choice of 2 SD cut-off was based on previous studies
showing it gives greater diagnostic certainty [22] and optimal sensitivity and specificity [23]. As we had only one
visuospatial test (pentagon copying from the MMSE), to
be consistent with our previous studies [11, 24], modified
level II criteria were used. From our cohort of 157 patients
with PD, 39 were diagnosed as PD-MCI. Seventy-four participants (42 controls, 23 PD-NC and 9 PD-MCI) did not
have baseline DTI scans and in two patients (1 PD-NC and
1 PD-MCI) the baseline DTI scan had technical problems
during acquisition. Nine controls had to be excluded as they
met the criteria for MCI and three patients (1 PD-NC and 2
PD-MCI) were excluded retrospectively as at follow-up they
were re-diagnosed as non-idiopathic PD. Therefore, the final
baseline cohort consisted of 168 participants (48 controls,
93 PD-NC and 27 PD-MCI). At follow-up, two participants
had died (1 PD-NC and 1 PD-MCI), twenty-nine did not
complete the assessments (11 controls, 13 PD-NC and 5
PD-MCI), and the scanner had technical problems during
the follow-up of two consecutive controls.

MRI acquisition
Participants had baseline and follow-up MRIs on the same
3T Intera Achieva scanner (Philips Medical Systems, Eindhoven, The Netherlands) with an eight-channel receiver
head coil. A whole-brain standard sagittal T1-weighted
volumetric scan was acquired using a magnetization prepared rapid gradient echo sequence: echo time = 4.6 ms;
repetition time = 9.6 ms; inversion time = 4.6 ms, flip
angle 8°, sensitivity encoding factor = 2; in-plane field
of view = 240 × 240 mm; slice thickness = 1.2 mm; voxel
size = 1.15 × 1.15 mm. DTI acquisitions were based on
a two-dimensional diffusion-weighted, spin-echo, echo
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planar imaging sequence with 59 slices: Repetition
time = 6100 ms; echo time = 70 ms; flip angle = 90°; voxel
size = 2.1 × 2.1 mm; slice thickness = 2.1 mm; field of
view = 270 × 270 mm. Diffusion weighting was performed
in 64 directions (diffusion b = 1000 s/mm2) and in six acquisitions without diffusion weighting (b = 0 s/mm2).

MRI pre‑processing
Voxel-based analysis of the DTI data was performed using
tract-based spatial statistics (TBSS) [25] in FSL (http://
www.fmrib.ox.ac.uk/fsl) 5.0.2 [26]. The baseline and follow-up total motion index were compared between groups:
no group differences were demonstrated either at baseline
or follow-up (Supplemental Data 1). After brain extraction,
eddy current-induced distortion and subject movements were
corrected using the Eddy FSL toolbox. FA and MD images
were created by fitting a tensor model to the raw diffusion
data. All FA images were aligned in the standard Montreal
Neurological Institute 152 (MNI152) space using the nonlinear registration tool. The mean of all aligned FA images
was created and thinned to build a mean FA skeleton representing the centres of all tracts common to all image volumes. The baseline skeleton was created using all subjects’
baseline images, whereas the longitudinal skeleton included
the baseline images of only those participants who completed the follow-up and their respective follow-up images
all-together. Each aligned FA image volume was projected
onto the common skeleton by filling the skeleton with FA
values from the nearest relevant tract center. The resulting
data were fed into the voxelwise cross-subject statistics. To
estimate the WM microstructural change over 18 months for
each participant, we subtracted each projected skeletonized
FA image at follow-up from their respective baseline image.
The difference images were then used in our statistical models. The same steps were followed for the MD images.

Data analyses
Image Analyses: Voxel-wise statistics were applied to the
skeletonized FA and MD data using the randomize tool
from FSL [27], which performed a 5000 permutation-based
testing using threshold-free cluster enhancement (p < 0.05),
corrected for multiple comparisons using the family-wise
error correction. Group differences regarding FA and MD
at baseline and interval changes at follow-up were tested
using General Linear Model. The designs matrix consisted
of t-contrasts with age, sex, education, levodopa equivalent
daily dose and, when appropriate, scan intervals and disease duration as covariates for comparison between disease
groups. White matter lesion volume (normalised to whole
brain volume) was assessed using the method of Firbank
et al. [28].

Clinical data: ANOVA (F) or two-sample Student’s t (t)
test were used to compare means between groups. When
ANOVA disclosed a significant main effect of group, post
hoc differences were assessed using post hoc Bonferroni
multiple-comparison tests. A Chi-square test (x2) was used
for categorical data comparison. The relationships between
baseline FA or MD with motor impairment and cognition
were tested using multiple linear regression models, where
baseline cognitive or motor scores were the dependent variables and FA or MD, the independent variables. These analyses were controlled for age, sex, education, disease duration
and levodopa equivalent daily dose. However, when testing if baseline FA or MD were independent predictors of
cognitive decline or worsening of motor impairment after
18 months, the follow-up cognitive or motor scores were
used as the dependent variables, and the analyses were also
controlled for baseline cognitive or motor scores and interval between visits. For all multiple regression analyses, we
extracted the total brain baseline values of MD and FA using
the ‘fslmeants’ tool from the FSL which extracts the average time series values of all selected voxels. All analyses
were performed in STATA version 14.1, all tests were twotailed, significant results are reported at p < 0.05. Due to the
high inter-dependency of the FA and MD measures and the
exploratory nature of this study, we did not apply Bonferroni
corrections for multiple testing when investigating within
group data.

Results
The baseline analyses were performed on the 168 participants (48 controls, 93 PD-NC and 27 PD-MCI) who completed the clinical assessment and had baseline DTI scans
that passed quality control. After a mean of 18.8 (SD 1.6)
months, 135 (35 controls, 79 PD-NC and 21 PD-MCI) participants completed the follow-up clinical assessment and
were re-scanned successfully. The baseline demographics
and clinical characteristics of participants are summarized
in Table 1.
The sex distribution between groups was not significantly different. Patients with PD-MCI were significantly
older than patients with PD-NC. Education was significantly different among groups, however, when interrogation with post hoc Bonferroni pairwise tests, no significant
differences were found. The proportion of WML was not
significantly different between groups. Disease duration
and motor impairment was similar in both groups. In addition, levodopa equivalent daily dose intake was not significantly different among groups. Compared to PD-NC,
patients with PD-MCI were significantly more affected as
evidenced by higher Hoehn and Yahr stages. The clinical
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Table 1  Baseline demographics and clinical characteristics
Characteristic

Control (n = 48)

PD-NC (n = 93)

PD-MCI (n = 27)

Statistic

p

Female, %
Age, years
Education, years
Proportion of WML
Time to follow-up, months
Duration of PD, months
UPDRS-III
Hoehn and Yahr
Levodopa equivalent dose, mg
Clinical phenotype, %
Postural instability/gait difficulty
Tremor dominance
Indeterminate

40%
66.0 (7.9)
13.7 (3.7)
0.003 (0.01)
20.0 (1.7)
–
–
–
–

34%
64.3 (10.8)
13.5 (3.8)
0.004 (0.01)
18.2 (1.3)
6.4 (0.5)
25.9 (1.1)
1.9 (0.1)
161.0 (13.7)

30%
70.5 (8.1)
11.6 (4.1)
0.007 (0.01)
19.0 (1.5)
5.6 (0.7)
29.2 (2.2)
2.3 (0.1)
214.0 (24.9)

–
–
–

44%
40%
15%

46%
35%
18%

x2(2) = 0.8
f(2, 165) = 4.3
f(2, 165) = 3.1
f(2, 165) = 1.8
f(2, 165) = 20.1
t(118) = 0.7
t(118) = 1.4
t(118) = 2.4
t(118) = 1.8
x2(2) = 0.4

0.671
0.015a, 0.011d
0.046a,e
0.174
< 0.001a, < 0.001b, 0.033c
0.466
0.176
0.018
0.069
0.813

Values expressed as mean (SD)

a
ANOVA, Post hoc Bonferroni pairwise tests: bControls versus PD-NC, cControls versus PD-MCI, dPD-NC versus PD-MCI, eno significant
results on pairwise tests

phenotype distribution was not significantly different
between the two groups of patients with PD (Table 1).

Baseline diffusion tensor imaging parameters
Patients with PD-MCI and PD-NC had significantly higher
white matter MD compared with controls in widespread
regions, involving bilaterally the corona radiata, internal and external capsule, corpus callosum, inferior and
superior fronto-occipital fasciculi, forceps minor, cingula,
superior and inferior longitudinal fasciculi (Fig. 1). There
were no significant differences in MD between PD-MCI
and PD-NC at baseline. In terms of FA, patients with PDMCI had significant lower FA than controls in posterior
aspect of the inferior fronto-occipital fasciculi, superior
and inferior longitudinal fasciculi, forceps major, corticospinal tracts and cingula (Fig. 1). No significant FA differences between the remaining groups.

Relationship between baseline diffusion tensor
imaging parameters and cognition
At baseline, among the patients with PD-MCI, higher MD
was significantly related to lower attention and executive
function scores. The relationships between the other cognitive functions or general cognition with FA or MD baseline values were not significant among any of the study
groups (Table 2).
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Relationship between baseline diffusion tensor
imaging parameters and motor function
Within the combined group of PD (PD-NC and PD-MCI),
the relationships between baseline motor impairment with
FA or MD were not significant (Table 3).
Regarding the motor phenotypes, there were no significant differences in terms of baseline FA (F(2, 117) 0.03, p
0.972) or MD (F(2, 117) 0.82, p 0.443) values.

Longitudinal diffusion tensor imaging parameters
At follow-up, there were significant changes in both DTI
parameters when compared to baseline, with FA decreasing and MD increasing significantly. However, compared to
PD-NC, the PD-MCI group showed significant MD changes,
increasing mainly in their frontal regions (Fig. 2). All these
changes followed a bilateral and symmetric pattern. There
were no significant differences in the change in MD in the
PD groups compared with controls. Similarly, FA changes
were not significantly different between groups.

Diffusion tensor imaging parameters as predictors
of decline in cognition
At follow-up, 15% (12 out of 79) of PD-NC progressed
to MCI and 14% (3 out of 21) of those participants with
baseline PD-MCI converted to dementia. Lower baseline
values of FA were significantly related with greater decline
in executive function scores among controls. Within the
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Fig. 1  Differences in baseline mean diffusivity. TBSS: regions at
baseline of increased mean diffusivity and reduce fractional anisotropy (p < 0.05 corrected) (a). Increased mean diffusivity between
patients with PD-NC and controls (b) between patients with PDMCI and controls. c Reduced fractional anisotropy between patients

with PD-MCI and controls. TBSS results are shown overlaid on an
MNI152 template and the mean FA skeleton (green). Significantly
different voxels of increased MD are shown in red shades and those
of reduced FA, in blue. Z-coordinates are displayed

participants with either PD-NC or PD-MCI, MD and FA
were not significantly related to cognitive scores (Table 4).
Among those patients with PD-NC, FA [β (95% CI) 0.001
(− 0.007; 0.009), p 0.787] and MD [β (95% CI) − 0.004
(− 0.017; 0.010), p 0.605] values were not predictors of
progression to MCI.

between baseline FA and motor impairment was not significant (Table 3).
Regarding the motor phenotypes, there were no significant differences in terms of longitudinal changes in FA [F(2,
97) 1.09, p 0.341] or MD [F(2, 97) 1.59, p 0.210] values.

Diffusion tensor imaging parameters as predictors
of decline in motor impairment
Within the combined group of PD (PD-NC and PD-MCI),
higher MD baseline values were significant predictors of
motor impairment worsening, however, the relationship

Discussion
This study showed that MD is a significant predictor of
worsening motor function in early Parkinson’s disease over
18 months. We also demonstrated that MD differed between
patients with Parkinson’s disease and controls even soon
after diagnosis. Furthermore, in patients with PD-MCI,
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Table 2  Multiple linear regression analyses examining the relationship between fractional anisotropy and mean diffusivity with cognitive in
patients with early Parkinson’s disease and controls
Tests

Controls
MMSE
Attention
Executive function
Language
Memory
Visuospatial function
PD-NC
MMSE
Attention
Executive function
Language
Memory
Visuospatial function
PD-MCI
MMSE
Attention
Executive function
Language
Memory
Visuospatial function

Baseline test scores

Baseline fractional anisotropy

Baseline mean diffusivity

Mean (SD)

β (95% CI)

p

β (95% CI) (× 103)

p

29.35 (0.81)
0.00 (0.80)
− 0.01 (0.70)
0.00 (0.80)
0.00 (0.77)
0.00 (1.00)

8.50 (− 5.59; 22.60)
0.57 (− 12.88; 14.03)
− 7.97 (− 19.33; 3.39)
3.09 (− 11.12; 17.30)
4.88 (− 8.52; 18.27)
− 3.13 (− 21.12; 14.86)

0.230
0.932
0.164
0.663
0.466
0.727

− 5.47 (− 15.52; 4.59)
0.10 (− 9.51; 9.71)
7.54 (− 0.35; 15.42)
1.83 (− 8.40; 12.06)
− 5.88 (− 15.35; 3.59)
0.42 (− 12.48; 13.31)

0.279
0.983
0.061
0.720
0.217
0.948

28.91 (1.05)
− 0.48 (1.04)
− 0.43 (0.70)
− 0.05 (0.87)
− 0.47 (0.93)
0.12 (0.73)

− 8.47 (− 23.37; 6.43)
3.14 (− 11.27; 17.55)
1.21 (− 7.70; 10.12)
− 0.49 (− 13.25; 12.27)
7.84 (− 4.58; 20.25)
2.65 (− 7.73; 13.03)

0.262
0.666
0.787
0.940
0.213
0.613

4.79 (− 4.81; 14.38)
2.78 (− 6.48; 12.04)
0.68 (− 5.04; 6.41)
5.10 (− 3.02; 13.22)
− 5.48 (− 13.35; 2.39)
− 2.54 (− 9.20; 4.12)

0.324
0.552
0.813
0.215
0.170
0.450

27.81 (1.69)
− 3.23 (2.83)
− 1.80 (1.21)
− 0.68 (1.10)
− 2.72 (1.70)
− 1.11 (2.54)

3.66 (− 35.53; 42.86)
47.12 (− 17.21; 111.45)
20.68 (− 6.29; 47.65)
− 4.26 (− 33.13; 24.61)
8.12 (− 29.76; 45.99)
− 39.48 (− 100.04; 21.07)

0.847
0.142
0.125
0.759
0.660
0.189

− 5.35 (− 30.53; 19.84)
− 42.63 (− 81.72; − 3.54)
− 20.43 (− 36.26; − 4.60)
11.55 (− 6.57; 29.66)
− 10.20 (− 34.29; 13.89)
12.41 (− 28.01; 52.83)

0.663
0.034
0.014
0.196
0.387
0.529

Each analysis was controlled for age, sex, education, disease duration and levodopa equivalent daily dose
Table 3  Multiple linear regression analyses examining the relationship between fractional anisotropy and mean diffusivity with motor
impairment in patients with early Parkinson’s disease
UPDRS-III
Baselinea
Fractional anisotropy
Mean diffusivity (× 103)
Follow-upb
Fractional anisotropy
Mean diffusivity (× 103)

β (95% CI)

p

− 3.92 (− 129.14; 121.29)
16.90 (− 63.57; 97.38)

0.951
0.678

− 102.51 (− 215.90; 10.88)
91.31 (16.74; 165.89)

0.076
0.017

a

Analyses were controlled for age, sex, education, disease duration
and levodopa equivalent daily dose

b

Analyses were controlled for age, sex, education, disease duration,
levodopa equivalent daily dose, baseline motor scores and interval
between visits

increased mean diffusivity was significantly associated with
attention and executive function impairments, and frontal
MD increased significantly faster when compared to those
with PD-NC.
The current results confirm our principal hypothesis,
and reinforce previous cross-sectional observations [18] of
greater cortical thinning in the frontal and temporal cortices
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in PD-MCI compared to cognitively normal patients. It suggests that both cortical integrity and connectivity of the frontal lobe are vital for successful cognitive function [29]. The
focal pattern of frontal white matter deterioration in PD-MCI
raises the possibility that there is a synergistically detrimental effect of disconnection and concurrent cortical atrophy
[18]. However, such causality cannot yet be confirmed with
our current results. Interestingly, both white matter microstructure and cortical thickness differences between the two
PD sub-groups only became evident after 18 months.
We demonstrated that in early PD-MCI, higher values
of MD are associated with lower attention and executive
function scores. For these analyses we did not correct for
multiple testing, however, our weak but significant p values are concordant with the previously published research
demonstrating that even slight changes in the white matter might be a contributing factor to the Parkinson’s disease dysexecutive syndrome [7]. Therefore, by accepting
the null hypothesis, we would most likely be incurring
in error type II as it is well known that the Bonferroni’s
correction is too conservative. Our findings support the
hypothesis that disruption of prefrontal connections to
the basal ganglia, represented by white matter microstructural changes are implicated in some of the cognitive
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Fig. 2  Differences in longitudinal mean diffusivity. TBSS: regions
at follow-up of increased mean diffusivity interval changes (p < 0.05
corrected) between patients with PD-MCI compared to those with

PD-NC. TBSS results are shown overlaid on an MNI152 template
and the mean FA skeleton (green). Significantly different voxels of
increased MD are shown in red shades. Z-coordinates are displayed

Table 4  Multiple regression analyses of fractional anisotropy or mean diffusivity as independent predictors of cognitive scores in patients with
early Parkinson’s disease and controls
Tests

Controls
MMSE
Attention
Executive function
Language
Memory
Visuospatial function
PD-NC
MMSE
Attention
Executive function
Language
Memory
Visuospatial function
PD-MCI
MMSE
Attention
Executive function
Language
Memory
Visuospatial function

Follow-up test scores

Baseline fractional anisotropy

Baseline mean diffusivity

Mean (SD)

β (95% CI)

p

β (95% CI) (× 103)

p

29.83 (0.45)
− 0.18 (0.86)
0.08 (0.63)
0.80 (0.63)
− 0.33 (0.85)
0.26 (0.00)

2.26 (− 7.80; 12.32)
2.12 (− 10.84; 15.07)
10.23 (1.38; 19.07)
− 1.92 (− 22.36; 18.51)
4.03 (− 10.09; 18.15)
1.59 (− 9.63; 12.81)

0.651
0.742
0.025
0.849
0.565
0.776

− 0.23 (− 6.78; 6.33)
2.48 (− 5.94; 10.90)
− 3.76 (− 10.02; 2.50)
0.57 (− 12.73; 13.87)
1.08 (− 8.33; 10.49)
− 0.41 (− 7.73; 6.91)

0.944
0.553
0.231
0.931
0.818
0.911

28.95 (1.30)
− 0.85 (1.37)
− 0.23 (0.88)
0.03 (0.69)
− 0.64 (1.19)
− 0.31 (1.57)

− 2.51 (− 20.89; 15.87)
4.05 (− 9.70; 17.81)
1.56 (− 9.96; 13.07)
3.35 (− 6.78; 13.49)
− 8.16 (− 21.55; 5.23)
7.92 (− 14.57; 30.41)

0.786
0.559
0.789
0.511
0.228
0.485

5.92 (− 5.57; 17.40)
− 0.57 (− 9.32; 8.19)
− 2.09 (− 9.39; 5.21)
− 1.96 (− 8.44; 4.52)
6.73 (− 1.56; 15.02)
1.78 (− 12.46; 16.02)

0.308
0.898
0.571
0.548
0.110
0.804

27.00 (1.79)
− 3.64 (3.40)
− 1.77 (0.99)
− 0.60 (1.08)
− 2.91 (1.60)
− 3.25 (3.72)

27.43 (− 15.88; 70.74)
4.64 (− 49.77; 59.05)
9.79 (− 10.54; 30.11)
4.49 (− 19.30; 28.27)
14.53 (− 21.53; 50.59)
62.76 (− 27.61; 153.13)

0.197
0.858
0.321
0.690
0.404
0.159

− 21.45 (− 51.05; 8.16)
− 4.18 (− 42.65; 34.29)
− 10.29 (− 24.03; 3.44)
− 3.57 (− 20.49; 13.35)
− 4.73 (− 30.95; 21.49)
− 29.54 (− 92.55; 33.47)

0.143
0.820
0.131
0.656
0.706
0.333

Each analysis was controlled for baseline test scores, age, sex, education, levodopa equivalent daily dose, disease duration and interview interval

features of PD. According to the classical “parallel loop”
model, homologous circuits connect frontal cortex to basal
ganglia and thalamus [30]. These circuits are related to
motor and oculomotor function, cognition and emotional
regulation. Particularly, the dorsolateral prefrontal circuit
that has been linked with PD, affecting executive function [31, 32]. We failed to demonstrate that MD and FA
values are predictors of cognitive decline. It may be that

18 months of interval was not long enough to demonstrate
such relationship.
A meta-analyses [33] on diffusion tensor imaging in PD
demonstrated that FA and MD values could distinguish
patients with PD from healthy controls in five regions: the
substantia nigra, the corpus callosum, the cingulate and temporal cortices, and the corticospinal tracts, the latter, being
associated with increased FA and decreased MD, suggesting
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possible brain reorganization. Furthermore, MD values only
could differentiate PD from controls in the putamen, globus
pallidum and internal capsules. We demonstrated that even
at early stages of PD, mean diffusivity is significantly higher
in the corona radiata, internal and external capsules, corpus
callosum, inferior and superior fronto-occipital fasciculi,
forceps minor, cingula, superior and inferior longitudinal
fasciculi, and FA is reduced in the posterior aspect of the
inferior fronto-occipital fasciculi, superior and inferior longitudinal fasciculi, forceps major, corticospinal tracts and
cingula.
Ofori et al. [34] investigated diffusional longitudinal
changes within the substantia nigra in Parkinson’s disease
using an advanced bi-tensor diffusion model and demonstrated that baseline elevated free-water levels in the posterior substantia nigra predicted 1 year worsening of bradykinesia and general cognitive decline. They suggested that
the progressive increase of free-water levels might be related
to the characteristic degeneration of dopaminergic cells in
the substantia nigra. Our study demonstrated that baseline
white matter MD values predicted 18 months worsening of
motor symptoms. Although we did not specifically measure
substantia nigra free water, it is possible that the findings
observed by Ofori et al. [34] and ours are interconnected
phenomena representing deficits of the substantia nigra
functional connectivity. Few other studies showed significant
correlations between motor impairment in PD and substantia nigra diffusional changes [34–36]. Rae et al. [7] identified correlation between impairment in motor function and
reduced fractional anisotropy beyond the substantia nigra,
in the white matter. Their findings were based on a crosssectional sample and no correlations were found between
mean diffusivity and motor features. In our study we failed
to identify cross-sectional associations between white matter tract microstructure and motor disability, however, we
demonstrated that baseline increased MD was predictive
of worsening of motor symptoms. This suggests that direct
presynaptic deposition of PD-related neurodegenerative
pathologies could lead to axonal degeneration impairing
structural connectivities. A combined DTI and graph analysis study found alterations in the structural connectivity of
several motor and non-motor regions present already at an
early stage of disease [37].
Given the well-established differences in disease progression according to the different motor phenotypes of
PIGD and TD in Parkinson’s disease [38], we investigated
the relationship between these phenotypes and DTI metrics. No significant differences were found at baseline or 18
months later: the longitudinal changes in MD and FA were
not significantly different according to phenotype. Similar
TBSS baseline findings were also previously demonstrated
[39], however, when probabilistic tractography was used,
increased MD was demonstrated in tracts connecting the
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right premotor cortex and right inferior parietal lobule in TD
compared to PIGD. Most previous studies that have reported
FA and MD differences according to clinical phenotypes
used tractography or region of interest rather than TBSS
[40], which is beyond the scope of our study.
The TBSS voxelwise analysis that we applied is an
automated observer-independent technique which reduces
potential bias because it does not require a priori selection
of regions of interest. Furthermore, no arbitrary spatial
smoothing is necessary, minimizing misalignment and misregistration, increasing the sensitivity and interpretability
of findings [25]. However, as a drawback TBSS has the disadvantage of only providing group comparisons of the DTI
parameters at the major white matter bundles without much
specificity, therefore, not informing which regions are connected by individual fibre tracts; furthermore, voxels further from tract centres decrease weighting in the average
of voxels projected to that location, thereby reducing the
sensitivity to detect changes in such locations [41]. This
potential lack of TBSS sensitivity added to the short disease duration of our patients with PD (6.0 ± 4.6 months)
might have impacted in our failure to demonstrate baseline
differences between the PD-NC and PD-MCI in terms of
white matter integrity, even though the two patients groups
were significantly different in terms of disease severity and
cognitive status. The cross-sectional study which used the
most comparable methodology to ours [8] involving TBSS
and grouping patients according to formal criteria to diagnose PD-MCI, also found that all PD groups had higher
MD values compared to controls. However, in contrast,
their patients with PD and cognitive impairment had higher
MD values than those with PD-NC. This might be explained
by their patients’ longer disease duration than in our study
(5.8 ± 5.1 years). In line with our findings, a longitudinal
study [42] demonstrated that PD patients and matched controls exhibited DTI changes over time. They suggested that
DTI PD-specific changes over 1 year did not extend beyond
the normal age-associated change. Unfortunately, among
their 19 participants with PD, only four had MCI, precluding subgroup analyses. Another longitudinal study using
TBSS [43], which followed patients with PD for 2 years, did
not demonstrate any significant time or group effects in FA
between PD and controls, or between PD-NC and PD-MCI.
The small number of participants (n 25) will have reduced
their power to detect subgroup differences.
In our study, white matter lesions were not significantly
different between groups. We did not include white matter hyperintensity volume as a covariate in our analyses as
we do not consider white matter hyperintensities as a confounder but part of a spectrum of the white matter changes.
Evidence from a large representative population-based
autopsy driven study [44] has shown that MRI detection of
white matter hyperintensities is less sensitive than pathology
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and false negative MRIs are associated with milder pathology. Furthermore, the same group [45] showed that the prevalence of white matter lesions is as high as 94% regardless
of dementia status. Abnormal DTI measures in white matter
tracts connecting key regions affected by Parkinson’s disease
pathology can also be affected by small-vessel disease and
white matter lesions, thereby making it difficult to disentangle vascular from non-vascular pathological processes
in Parkinson’s disease and PD-MCI. Our main interest was
to characterise the trajectories of DTI metrics in Parkinson’s
disease irrespective of the pathological process that is contributing to the white matter changes, hence not including
white matter lesions as a covariate.
Our diffusion imaging protocol prioritized a large number of gradient directions (64), enabling greater angular
resolution, therefore, a more accurate FA estimation [7].
However, we demonstrated only modest FA differences at
baseline and did not demonstrate FA changes at follow-up.
It may be that fractional anisotropy reduction only occurs
later in the course of disease progression. Our cohort comprised newly diagnosed Parkinson’s disease cases who had
very short disease duration. It is possible that MD measurements are inherently more sensitive than FA for detecting
differences in white matter microstructure as MD is more
uniform across the brain than FA, and therefore, less affected
by registration errors in relation to voxel size [43]. Furthermore, while MD characterizes the mean diffusion along both
axonal and radial orientations, revealing how restricted diffusion is within the white matter, FA characterizes diffusion in the axonal orientation relative to radial orientations,
representing the degree of directional diffusion [7, 46]. If
MD is sensitive but directionally non-specific, any process
leading to white matter microstructural degeneration would
cause MD to invariably increase, whereas FA provides more
specific information as it depends on the underlying arrangement of the fibres [46]. Even so, some authors also consider
FA to be non-specific because decreases may result from
either increased radial (perpendicular) diffusivity or reduced
axial (parallel) diffusivity [47].
This study has some limitations. First, our patients with
PD-MCI were significantly older with the more advanced
disease than the PD-NC. Even though we adjusted the analyses for age, this is a potential bias as older patients with
PD have a faster rate of disease progression than those at
younger ages [48]. We, therefore, performed a series of sensitivity analyses selecting subsets of older and with more
advanced disease patients with PD-NC and found that our
results remained robust (Online Table e-1). Second, some
participants left the study before the second MRI acquisition. As the TBSS implementation of its general linear
model does not accommodate incomplete datasets, we could
not adjust for missing data by means or imputation. However, it is unlikely to have significantly influenced our main

results, as there were no significant differences between
those who left the study and those who continued regarding demographics and clinical features (Online Table e-2).
Third, the gap between MRI studies was significantly higher
among controls, and they had the highest drop-out rate. This
probably influenced our power to detect significant differences. Finally, it should also be noted that PD patients were
assessed while taking their medication which might have
influenced some aspects of cognition [49], but is unlikely
to have significantly altered the diffusion metrics [7]. However, in contrast to most other studies, we included levodopa
equivalent dose in our analyses [20].
This study with a prospective longitudinal design, allowed
us to evaluate white matter microstructure, at baseline and
at 18 months, to assess the potential for DTI in predicting
cognitive decline and worsening of motor function. Our
results are derived from a well-characterized, large cohort
of patients with early PD, with and without MCI based on
consensus MDS criteria. Our images were gathered all at
one site and analyzed using a TBSS approach which enables a rather unbiased analysis. We demonstrated that WM
microstructural changes can differentiate between Parkinson’s disease and controls even in early stages of disease
and MD is associated with attention and executive function
impairment in PD-MCI. Furthermore, MD is a predictor of
future worsening of motor impairment. We also showed that
in PD-MCI, the frontal mean diffusivity increases significantly more in PD-MCI than in PD without MCI. Our findings support the hypothesis that MD represents an important
correlate of cognitive function and is a predictor of motor
decline in PD. As such diffusion tensor imaging is potentially a useful tool in stratification of patients into clinical
trials to monitor the impact of treatment on motor and cognitive features.
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